-
Seoul leads rebound across Asian stocks, oil extends gains
-
Tourism on hold as Middle East war casts uncertainty
-
Bayern and Kane gambling with house money as Gladbach come to town
-
Turkey invests in foreign legion to deliver LA Olympics gold
-
Galthie's France blessed with unprecedented talent: Saint-Andre
-
Voice coach to the stars says Aussie actors nail tricky accents
-
Rahm rejection of DP World Tour deal 'a shame' - McIlroy
-
Israel keeps up Lebanon strikes as ground forces advance
-
China prioritises energy and diplomacy over Iran support
-
Canada PM Carney says can't rule out military participation in Iran war
-
Verstappen says new Red Bull car gave him 'goosebumps'
-
Swiss to vote on creating giant 'climate fund'
-
Google to open German centre for 'AI development'
-
Winter Paralympics to start with icy blast as Ukraine lead ceremony boycott
-
Sci-fi without AI: Oscar nominated 'Arco' director prefers human touch
-
Ex-guerrillas battle low support in Colombia election
-
'She's coming back': Djokovic predicts Serena return
-
Hamilton vows 'no holding back' in his 20th Formula One season
-
Two-thirds of Cuba, including Havana, hit by blackout
-
US sinks Iranian warship off Sri Lanka as war spreads
-
After oil, US moves to secure access to Venezuelan minerals
-
Arteta hits back at Brighton criticism after Arsenal boost title bid
-
Carrick says 'defeat hurts' after first loss as Man Utd boss
-
Ecuador expels Cuba envoy, rest of mission
-
Arsenal stretch lead at top of Premier League as Man City falter
-
Title race not over vows Guardiola after Man City held by Forest
-
Rosenior hails 'world class' Joao Pedro after hat-trick crushes Villa
-
Brazil ratifies EU-Mercosur trade deal
-
Real Sociedad edge rivals Athletic to reach Copa del Rey final
-
Chelsea boost top four push as Joao Pedro treble routs Villa
-
Leverkusen sink Hamburg to keep in touch with top four
-
Love match: WTA No. 1 Sabalenka announces engagement
-
Man City falter as Premier League leaders Arsenal go seven points clear
-
Man City title bid rocked by Forest draw
-
Defending champ Draper ready to ramp up return at Indian Wells
-
Arsenal extend lead in title race after Saka sinks Brighton
-
US, European stocks rise as oil prices steady; Asian indexes tumble
-
Trump rates Iran war as '15 out of 10'
-
Nepal votes in key post-uprising polls
-
US Fed warns 'economic uncertainty' weighing on consumers
-
Florida family sues Google after AI chatbot allegedly coached suicide
-
Alcaraz unbeaten run under threat from Sinner, Djokovic at Indian Wells
-
Iran's supreme leader gone, but opposition still at war with itself
-
Mideast war rekindles European fears over soaring gas prices
-
'Miracle to walk' says golfer after lift shaft fall
-
'Nothing is working': Gulf travel turmoil hits Berlin tourism fair
-
Harvey Weinstein rape retrial to start April 14: publicist
-
No choke but 'walloping', South Africa coach says of T20 flop
-
Bayer gets preliminary approval for weedkiller class settlement
-
Russia to free two Hungarian-Ukrainian POWs, Putin says
US medical agency will scale back testing on monkeys
The United States will scale back certain drug-safety testing requirements on monkeys, federal regulators said Tuesday, marking the latest step by President Donald Trump's administration to limit the use of animals in research.
Under new draft guidance from the Food and Drug Administration, computer models, lab-grown mini-organs, and human studies will replace the use of non-human primates in testing monoclonal antibodies -- lab-engineered proteins used to treat cancers, autoimmune conditions and other diseases.
"We are delivering on our roadmap commitment to eliminate animal testing requirements in drug evaluation and our promise to accelerate cures and meaningful treatments for Americans," FDA Commissioner Marty Makary said in a statement.
The statement added that typical nonclinical programs involving monoclonal antibodies could include more than 100 macaque monkeys -- apes are no longer used in any invasive research in the US -- yet often do not yield human-approved treatments.
The move was welcomed by animal-advocacy groups.
Zaher Nahle, a former animal researcher who is now the senior scientific advisor for nonprofit Center for a Humane Economy, told AFP the move was an "important step."
"These primates are not reliable in terms of predicting the toxicity, so you can get at least equal or better results in terms of your accuracy in predicting toxicology using other approaches," he added.
What's more, he noted, studies show that more than 90 percent of drugs deemed safe and effective in animals fail to win approval for human use.
The FDA's announcement follows a report in the journal Science last month that the Centers for Disease Control and Prevention would close its primate labs.
It "moves us one step closer to wiping out the federal government's wasteful monkey business," Justin Goodman of White Coat Waste Project told AFP.
But the National Institutes of Health -- the country's primary biomedical research agency -- remains a notable "outlier," he added. According to public data, 7,700 primates are confined in federal government labs and breeding facilities, of which 6,700 are at NIH.
Advocates of animal research have pushed back.
"Poorly planned transitions -- including premature study termination -- can place animals at serious risk and may undermine years of scientific investment intended to strengthen public health preparedness and advance lifesaving medical progress," advocacy group Americans for Medical Progress said after the CDC news was reported.
Proponents of animal testing say the research has been indispensable for major medical advances, including vaccines for diphtheria, yellow fever, measles and Covid-19.
Critics counter that decades-old laws have created regulatory lock-in, that publication incentives reward animal studies in top journals, and that a lucrative "animal-industrial complex" has helped entrench the status quo.
K.Hofmann--VB